176 related articles for article (PubMed ID: 28259941)
1. Consumption of policosanol enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat in young and middle-aged subjects.
Kim JY; Kim SM; Kim SJ; Lee EY; Kim JR; Cho KH
Int J Mol Med; 2017 Apr; 39(4):889-899. PubMed ID: 28259941
[TBL] [Abstract][Full Text] [Related]
2. Consumption of Cuban Policosanol Improves Blood Pressure and Lipid Profile via Enhancement of HDL Functionality in Healthy Women Subjects: Randomized, Double-Blinded, and Placebo-Controlled Study.
Cho KH; Kim SJ; Yadav D; Kim JY; Kim JR
Oxid Med Cell Longev; 2018; 2018():4809525. PubMed ID: 29854085
[TBL] [Abstract][Full Text] [Related]
3. Blood Pressure Lowering Effect of Cuban Policosanol is Accompanied by Improvement of Hepatic Inflammation, Lipoprotein Profile, and HDL Quality in Spontaneously Hypertensive Rats.
Cho KH; Yadav D; Kim SJ; Kim JR
Molecules; 2018 May; 23(5):. PubMed ID: 29751583
[TBL] [Abstract][Full Text] [Related]
4. Concomitant use of policosanol and beta-blockers in older patients.
Castaño G; Mas R; Gámez R; Fernández J; Illnait J; Fernández L; Mendoza S; Mesa M; Gutiérrez JA; López E
Int J Clin Pharmacol Res; 2004; 24(2-3):65-77. PubMed ID: 15689053
[TBL] [Abstract][Full Text] [Related]
5. Anti-Aging and Tissue Regeneration Ability of Policosanol Along with Lipid-Lowering Effect in Hyperlipidemic Zebrafish via Enhancement of High-Density Lipoprotein Functionality.
Lee EY; Yoo JA; Lim SM; Cho KH
Rejuvenation Res; 2016 Apr; 19(2):149-58. PubMed ID: 26413884
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy of Cuban Policosanol (Raydel
Cho KH; Nam HS; Kim NY; Lee MS; Kang DJ
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38276005
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of High-Density Lipoprotein Cholesterol Functions by Encapsulation of Policosanol Exerts Anti-Senescence and Tissue Regeneration Effects Via Improvement of Anti-Glycation, Anti-Apoptosis, and Cholesteryl Ester Transfer Inhibition.
Lim SM; Yoo JA; Lee EY; Cho KH
Rejuvenation Res; 2016 Feb; 19(1):59-70. PubMed ID: 26161621
[TBL] [Abstract][Full Text] [Related]
8. Elevated HDL2-paraoxonase and reduced CETP activity are associated with a dramatically lower ratio of LDL-cholesterol/total cholesterol in a hypercholesterolemic and hypertriglyceridemic patient.
Lee JH; Park JH; Lee SH; Kim JR; Cho KH
Int J Mol Med; 2010 Jun; 25(6):945-51. PubMed ID: 20428800
[TBL] [Abstract][Full Text] [Related]
9. Common variation in cholesteryl ester transfer protein: relationship of first major adverse cardiovascular events with the apolipoprotein B/apolipoprotein A-I ratio and the total cholesterol/high-density lipoprotein cholesterol ratio.
Kappelle PJ; Gansevoort RT; Hillege HJ; Wolffenbuttel BH; Dullaart RP;
J Clin Lipidol; 2013; 7(1):56-64. PubMed ID: 23351584
[TBL] [Abstract][Full Text] [Related]
10. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia.
Castaño G; Más R; Fernández JC; Fernández L; Illnait J; López E
Drugs R D; 2002; 3(3):159-72. PubMed ID: 12099160
[TBL] [Abstract][Full Text] [Related]
11. Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits.
Gámez R; Máz R; Arruzazabala ML; Mendoza S; Castaño G
Drugs R D; 2005; 6(1):11-9. PubMed ID: 15806713
[TBL] [Abstract][Full Text] [Related]
12. A deficiency of cholesteryl ester transfer protein whose serum remnant-like particle-triglyceride significantly increased, but serum remnant-like particle-cholesterol did not after an oral fat load.
Ai M; Tanaka A; Shimokado K; Ohtani R; Inazu A; Kobayashi J; Mabuchi H; Nakano T; Nakajima K
Ann Clin Biochem; 2009 Nov; 46(Pt 6):457-63. PubMed ID: 19641010
[TBL] [Abstract][Full Text] [Related]
13. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
[TBL] [Abstract][Full Text] [Related]
14. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus.
Castaño G; Menéndez R; Más R; Amor A; Fernández JL; González RL; Lezcay M; Alvarez E
Int J Clin Pharmacol Res; 2002; 22(3-4):89-99. PubMed ID: 12837046
[TBL] [Abstract][Full Text] [Related]
15. The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity.
Park KH; Shin DG; Kim JR; Hong JH; Cho KH
Int J Mol Med; 2010 Jan; 25(1):129-36. PubMed ID: 19956911
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
Crespo N; Illnait J; Más R; Fernández L; Fernández J; Castaño G
Int J Clin Pharmacol Res; 1999; 19(4):117-27. PubMed ID: 10939029
[TBL] [Abstract][Full Text] [Related]
17. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
[TBL] [Abstract][Full Text] [Related]
18. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.
Clark RW; Sutfin TA; Ruggeri RB; Willauer AT; Sugarman ED; Magnus-Aryitey G; Cosgrove PG; Sand TM; Wester RT; Williams JA; Perlman ME; Bamberger MJ
Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):490-7. PubMed ID: 14739125
[TBL] [Abstract][Full Text] [Related]
19. The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides.
Borggreve SE; Hillege HL; Wolffenbuttel BH; de Jong PE; Bakker SJ; van der Steege G; van Tol A; Dullaart RP;
J Clin Endocrinol Metab; 2005 Jul; 90(7):4198-204. PubMed ID: 15840744
[TBL] [Abstract][Full Text] [Related]
20. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
